The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Dapagliflozin (Forxiga®) has been accepted for use in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
During March 2021 Clinical Knowledge Summaries were published or updated in the following areas.
The Platelets - abnormal counts and cancer topic is new. The other topics have been reviewed and updated in keeping with current guidance with minor layout changes. The Contraception - progestogen-only methods topic has been updated in line with Faculty of Sexual and Reproductive Healthcare (FSRH) guidance and references to some retired QOF indicators have been removed. The Itch - widespread topic has been updated to recommend the use of non-sedating oral antihistamines first line unless there is a history of troublesome nocturnal itch. As such new sections on cetirizine, loratadine and fexofenadine have been added to the section on Prescribing information.
Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.